M Leo1, L Bartalena2, G Rotondo Dottore1, E Piantanida1, P Premoli2, I Ionni1, M Di Cera2, E Masiello2, L Sassi2, M L Tanda1, F Latrofa1, P Vitti1, C Marcocci1, M Marinò3. 1. Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy. 2. Department of Clinical and Experimental Medicine, Endocrinology Unit, University of Insubria, Viale Borri 57, 21100, Varese, Italy. 3. Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy. michele.marino@med.unipi.it.
Abstract
OBJECTIVE: In spite of previous conflicting results, an adjuvant role of selenium in the treatment of Graves' disease (GD) hyperthyroidism has been proposed. To address this issue, a randomized clinical trial was carried out aimed at investigating whether selenium is beneficial on the short-term control of GD hyperthyroidism treated with methimazole (MMI). METHODS:Thirty newly diagnosed hyperthyroid GD patients were randomly assigned to treatment with: (i) MMI or (ii) MMI plus selenium. Primary outcomes were: control of hyperthyroidism and clinical and biochemical manifestations of hyperthyroidism [heart rate, cholesterol, sex hormone-binding globulin (SHBG), hyperthyroidism symptoms] at 90 days. RESULTS: Baseline features of the two groups did not differ. Serum selenium at baseline was similar in the two groups and within the recommended range to define selenium sufficiency. Selenium increased with treatment in the MMI-selenium group and became significantly higher than in the MMI group. Serum malondialdehyde, a marker of oxidative stress, was similar in the two groups and decreased significantly with treatment, with no difference between groups. Administration of MMI was followed by a reduction of FT3 and FT4, with no difference between groups. Heart rate, SHBG and symptoms of hyperthyroidism decreased, whereas total cholesterol increased in both groups with no difference between groups. CONCLUSIONS: Our study, carried out in a selenium-sufficient cohort of GD patients, failed to show an adjuvant role of selenium in the short-term control of hyperthyroidism. However, selenium might be beneficial in patients from selenium-deficient areas, as well as in the long-term outcome of antithyroid treatment.
RCT Entities:
OBJECTIVE: In spite of previous conflicting results, an adjuvant role of selenium in the treatment of Graves' disease (GD) hyperthyroidism has been proposed. To address this issue, a randomized clinical trial was carried out aimed at investigating whether selenium is beneficial on the short-term control of GD hyperthyroidism treated with methimazole (MMI). METHODS: Thirty newly diagnosed hyperthyroid GDpatients were randomly assigned to treatment with: (i) MMI or (ii) MMI plus selenium. Primary outcomes were: control of hyperthyroidism and clinical and biochemical manifestations of hyperthyroidism [heart rate, cholesterol, sex hormone-binding globulin (SHBG), hyperthyroidism symptoms] at 90 days. RESULTS: Baseline features of the two groups did not differ. Serum selenium at baseline was similar in the two groups and within the recommended range to define selenium sufficiency. Selenium increased with treatment in the MMI-selenium group and became significantly higher than in the MMI group. Serum malondialdehyde, a marker of oxidative stress, was similar in the two groups and decreased significantly with treatment, with no difference between groups. Administration of MMI was followed by a reduction of FT3 and FT4, with no difference between groups. Heart rate, SHBG and symptoms of hyperthyroidism decreased, whereas total cholesterol increased in both groups with no difference between groups. CONCLUSIONS: Our study, carried out in a selenium-sufficient cohort of GDpatients, failed to show an adjuvant role of selenium in the short-term control of hyperthyroidism. However, selenium might be beneficial in patients from selenium-deficient areas, as well as in the long-term outcome of antithyroid treatment.
Authors: K Komosinska-Vassev; K Olczyk; E J Kucharz; C Marcisz; K Winsz-Szczotka; A Kotulska Journal: Clin Chim Acta Date: 2000-10 Impact factor: 3.786
Authors: D Esposito; M Rotondi; G Accardo; G Vallone; G Conzo; G Docimo; F Selvaggi; C Cappelli; L Chiovato; D Giugliano; D Pasquali Journal: J Endocrinol Invest Date: 2016-08-29 Impact factor: 4.256
Authors: Liliana N Guerra; María Del Carmen Ríos de Molina; Eliana A Miler; Silvia Moiguer; Mirta Karner; José A Burdman Journal: Clin Chim Acta Date: 2005-02 Impact factor: 3.786
Authors: C R de Farias; B R Cardoso; G M B de Oliveira; I C de Mello Guazzelli; R M Catarino; M C Chammas; S M F Cozzolino; M Knobel Journal: J Endocrinol Invest Date: 2015-04-17 Impact factor: 4.256
Authors: G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2017-12-18 Impact factor: 4.256
Authors: G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2017-06-27 Impact factor: 4.256
Authors: C Di Dato; D Gianfrilli; E Greco; M Astolfi; S Canepari; A Lenzi; A M Isidori; E Giannetta Journal: J Endocrinol Invest Date: 2017-04-09 Impact factor: 4.256
Authors: Elena Sabini; Marenza Leo; Barbara Mazzi; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò Journal: Eur Thyroid J Date: 2017-06-26